vs
Side-by-side financial comparison of MEDIFAST INC (MED) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.
PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $75.1M, roughly 1.1× MEDIFAST INC). On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -36.9%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs -34.4%).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.
MED vs PRCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $83.1M |
| Net Profit | — | $-31.6M |
| Gross Margin | 69.4% | 64.9% |
| Operating Margin | -10.4% | -4.1% |
| Net Margin | — | -38.1% |
| Revenue YoY | -36.9% | 20.2% |
| Net Profit YoY | — | -27.9% |
| EPS (diluted) | $-1.64 | $-0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $83.1M | ||
| Q4 25 | $75.1M | $76.4M | ||
| Q3 25 | $89.4M | $83.3M | ||
| Q2 25 | $105.6M | $79.2M | ||
| Q1 25 | $115.7M | $69.2M | ||
| Q4 24 | $119.0M | $68.2M | ||
| Q3 24 | $140.2M | $58.4M | ||
| Q2 24 | $168.6M | $53.4M |
| Q1 26 | — | $-31.6M | ||
| Q4 25 | — | $-29.8M | ||
| Q3 25 | $-2.3M | $-21.4M | ||
| Q2 25 | $2.5M | $-19.6M | ||
| Q1 25 | $-772.0K | $-24.7M | ||
| Q4 24 | — | $-18.9M | ||
| Q3 24 | $1.1M | $-21.0M | ||
| Q2 24 | $-8.2M | $-25.6M |
| Q1 26 | — | 64.9% | ||
| Q4 25 | 69.4% | 60.6% | ||
| Q3 25 | 69.5% | 64.8% | ||
| Q2 25 | 72.6% | 65.4% | ||
| Q1 25 | 72.8% | 63.9% | ||
| Q4 24 | 74.1% | 64.0% | ||
| Q3 24 | 75.4% | 63.2% | ||
| Q2 24 | 73.2% | 59.0% |
| Q1 26 | — | -4.1% | ||
| Q4 25 | -10.4% | -40.6% | ||
| Q3 25 | -4.6% | -27.8% | ||
| Q2 25 | -1.0% | -28.0% | ||
| Q1 25 | -1.1% | -39.7% | ||
| Q4 24 | 0.6% | -28.9% | ||
| Q3 24 | 1.5% | -38.4% | ||
| Q2 24 | -4.7% | -50.3% |
| Q1 26 | — | -38.1% | ||
| Q4 25 | — | -39.1% | ||
| Q3 25 | -2.5% | -25.7% | ||
| Q2 25 | 2.3% | -24.7% | ||
| Q1 25 | -0.7% | -35.8% | ||
| Q4 24 | — | -27.6% | ||
| Q3 24 | 0.8% | -35.9% | ||
| Q2 24 | -4.8% | -48.0% |
| Q1 26 | — | $-0.56 | ||
| Q4 25 | $-1.64 | $-0.54 | ||
| Q3 25 | $-0.21 | $-0.38 | ||
| Q2 25 | $0.22 | $-0.35 | ||
| Q1 25 | $-0.07 | $-0.45 | ||
| Q4 24 | $0.08 | $-0.34 | ||
| Q3 24 | $0.10 | $-0.40 | ||
| Q2 24 | $-0.75 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $245.6M |
| Total DebtLower is stronger | — | $51.7M |
| Stockholders' EquityBook value | $198.9M | $347.7M |
| Total Assets | $248.0M | $487.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.6M | ||
| Q4 25 | $167.3M | $286.5M | ||
| Q3 25 | $173.5M | $294.3M | ||
| Q2 25 | $162.7M | $302.7M | ||
| Q1 25 | $164.6M | $316.2M | ||
| Q4 24 | $162.3M | $333.7M | ||
| Q3 24 | $170.0M | $196.8M | ||
| Q2 24 | $163.5M | $214.1M |
| Q1 26 | — | $51.7M | ||
| Q4 25 | — | $51.6M | ||
| Q3 25 | — | $51.6M | ||
| Q2 25 | — | $51.5M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $51.5M | ||
| Q3 24 | — | $51.4M | ||
| Q2 24 | — | $51.4M |
| Q1 26 | — | $347.7M | ||
| Q4 25 | $198.9M | $365.9M | ||
| Q3 25 | $214.7M | $380.3M | ||
| Q2 25 | $216.0M | $385.8M | ||
| Q1 25 | $211.0M | $389.2M | ||
| Q4 24 | $210.1M | $402.2M | ||
| Q3 24 | $207.3M | $241.2M | ||
| Q2 24 | $205.3M | $251.8M |
| Q1 26 | — | $487.1M | ||
| Q4 25 | $248.0M | $508.1M | ||
| Q3 25 | $268.2M | $511.5M | ||
| Q2 25 | $269.3M | $513.1M | ||
| Q1 25 | $280.0M | $519.4M | ||
| Q4 24 | $284.2M | $534.0M | ||
| Q3 24 | $291.2M | $374.1M | ||
| Q2 24 | $293.5M | $374.4M |
| Q1 26 | — | 0.15× | ||
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.13× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.20× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | — |
| Free Cash FlowOCF − Capex | $-6.6M | — |
| FCF MarginFCF / Revenue | -8.8% | — |
| Capex IntensityCapex / Revenue | 1.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-5.3M | $-10.3M | ||
| Q3 25 | $12.1M | $-6.6M | ||
| Q2 25 | $-3.4M | $-15.0M | ||
| Q1 25 | $3.4M | $-17.0M | ||
| Q4 24 | $-4.9M | $-32.4M | ||
| Q3 24 | $9.1M | $-18.8M | ||
| Q2 24 | $13.1M | $-15.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-6.6M | $-12.2M | ||
| Q3 25 | $10.8M | $-9.5M | ||
| Q2 25 | $-4.8M | $-17.8M | ||
| Q1 25 | $1.9M | $-18.8M | ||
| Q4 24 | $-7.2M | $-33.6M | ||
| Q3 24 | $7.7M | $-19.0M | ||
| Q2 24 | $11.1M | $-16.8M |
| Q1 26 | — | — | ||
| Q4 25 | -8.8% | -15.9% | ||
| Q3 25 | 12.0% | -11.4% | ||
| Q2 25 | -4.5% | -22.5% | ||
| Q1 25 | 1.6% | -27.2% | ||
| Q4 24 | -6.1% | -49.2% | ||
| Q3 24 | 5.5% | -32.6% | ||
| Q2 24 | 6.6% | -31.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | 2.4% | ||
| Q3 25 | 1.5% | 3.4% | ||
| Q2 25 | 1.3% | 3.5% | ||
| Q1 25 | 1.3% | 2.7% | ||
| Q4 24 | 1.9% | 1.7% | ||
| Q3 24 | 1.0% | 0.4% | ||
| Q2 24 | 1.1% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.36× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.04× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MED
Segment breakdown not available.
PRCT
| Handpieces and other consumables | $43.0M | 52% |
| System sales and rentals | $23.4M | 28% |
| Other | $11.1M | 13% |
| Service | $5.6M | 7% |
